Boston Scientific Files S-4/A Amendment

Ticker: BSX · Form: S-4/A · Filed: Mar 30, 2026 · CIK: 0000885725

Boston Scientific CORP S-4/A Filing Summary
FieldDetail
CompanyBoston Scientific CORP (BSX)
Form TypeS-4/A
Filed DateMar 30, 2026
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $0.01, $374.00, $96.59, $267.83
Sentimentneutral

Sentiment: neutral

Topics: registration-statement, business-combination, amendment

TL;DR

BSC filed an S-4/A on 3/30/26 for a business combination. Lots of graphics in exhibits.

AI Summary

Boston Scientific Corporation filed an S-4/A amendment on March 30, 2026, related to the registration of securities in connection with a business combination. The filing includes various exhibits detailing financial information and corporate actions, with a significant number of graphic files suggesting visual representations of performance data.

Why It Matters

This filing is a procedural step for Boston Scientific, indicating ongoing or upcoming corporate actions such as mergers, acquisitions, or significant stock issuances that could impact the company's structure and shareholder value.

Risk Assessment

Risk Level: medium — S-4/A filings often precede significant corporate events like M&A, which carry inherent risks and uncertainties.

Key Players & Entities

FAQ

What is the primary purpose of this S-4/A filing?

The S-4/A filing is an amendment related to the registration of securities in connection with a business combination.

When was this S-4/A filing accepted by the SEC?

The filing was accepted on March 30, 2026.

What type of documents are included in this filing?

The filing includes the main S-4/A document, exhibits such as legal opinions (EX-5.1), consent letters from accountants (EX-23.1, EX-23.2, EX-23.3), and numerous graphic files (EX-99.1 through EX-99.3 and others) likely containing financial performance data.

Does this filing indicate a specific business combination event?

The filing explicitly states it is for 'Registration of securities, business combinations', indicating it pertains to such events, but the specific details of the combination are not provided in the filing metadata.

What is the total size of the main S-4/A document?

The main S-4/A document (tm266847-3_s4a.htm) is 5939675 bytes.

Filing Stats: 4,575 words · 18 min read · ~15 pages · Grade level 16.4 · Accepted 2026-03-30 07:14:57

Key Financial Figures

Filing Documents

From the Filing

tm266847-3_s4a - block - 59.2577784s TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 30, 2026 Registration No. 333-293872 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOSTON SCIENTIFIC CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 3841 04-2695240 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 300 Boston Scientific Way Marlborough, Massachusetts, 01752 (508) 683-4000 (Address, including Zip Code, and Telephone Number, including Area Code, of Registrant's Principal Executive Offices) Vance R. Brown Senior Vice President, General Counsel and Corporate Secretary Boston Scientific Corporation 300 Boston Scientific Way Marlborough, Massachusetts, 01752 (508) 683-4000 (Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service) Copies to: Clare O'Brien, Esq. Derrick Lott, Esq. Richard Alsop, Esq. Allen Overy Shearman Sterling US LLP 599 Lexington Avenue New York, New York 10022 (212) 848-4000 Johanna Roberts Executive Vice President, General Counsel and Secretary Penumbra, Inc. One Penumbra Place Alameda, California 94502 (510) 748-3200 Alan Denenburg, Esq. Michael Diz, Esq. Davis Polk & Wardwell LLP 900 Middlefield Road Redwood City, CA 94063 (650) 752-2000 Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after this registration statement becomes effective and upon completion of the merger described herein. If the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box. If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the SEC, acting pursuant to said Section 8(a), may determine. TABLE OF CONTENTS The information in the accompanying proxy statement/prospectus is not complete and may be changed. A registration statement relating to the shares of Boston Scientific Corporation common stock to be issued in the merger described herein has been filed with the Securities and Exchange Commission. These securities may not be issued until the registration statement filed with the Securities and Exchange Commission is effective. The accompanying proxy statement/prospectus is not an offer to sell these securities and does not constitute the solicitation of an offer to buy these securities in any jurisdiction where the offer or sale of these securities is not permitted. PRELIMINARY PROXY STATEMENT/PROSPECTUS MERGER PROPOSED—YOUR VOTE IS VERY IMPORTANT [ ] , 2026 Dear Stockholder of Penumbra, Inc.: On behalf of the Board of Directors of Penumbra, Inc., which we refer to as "Penumbra," we are pleased to enclose

View Full Filing

View this S-4/A filing on SEC EDGAR

View on Read The Filing